Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link?
Related Experiment Video
Updated: Nov 2, 2025

A Novel Stretching Platform for Applications in Cell and Tissue Mechanobiology
Published on: June 3, 2014
1Sapienza University, Dept. of Medicine and Cardiology, Via Lima 35, Rome, 00198, Italy.
Insights
Heterozygous familial hypercholesterolemia (heFH) can cause early heart dysfunction, even in asymptomatic individuals. This study found reduced heart strain and increased blood pressure in heFH patients, suggesting preclinical cardiovascular changes.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Dyslipidemia, particularly heterozygous familial hypercholesterolemia (heFH), is a significant risk factor for premature atherosclerotic cardiovascular disease.
- Subclinical cardiac dysfunction can be assessed using speckle-tracking echocardiography, evaluating myocardial deformation indices.
- Previous studies indicated decreased longitudinal and circumferential strain in heFH patients without comorbidities.
Discussion:
- This study investigated asymptomatic, treatment-naive heFH individuals with normal ejection fraction and no other major risk factors.
- A slight impairment in global longitudinal strain was observed despite normal standard echocardiographic parameters.
- Elevated systolic and diastolic blood pressure during exercise treadmill testing in heFH patients may indicate early preclinical hypertension.
Key Insights:
- Asymptomatic heFH males exhibit reduced left ventricular strain and increased systolic/diastolic blood pressure.
- High cholesterol levels may contribute to endothelial dysfunction and subsequent cardiovascular damage.
- These findings highlight potential early cardiovascular changes in heFH patients.
Outlook:
- Further research should explore the link between myocardial strain impairment and the development of systemic arterial hypertension in hypercholesterolemic individuals.
- Investigating the long-term cardiovascular outcomes in this patient group is warranted.
- Understanding these preclinical changes can inform early intervention strategies for heFH.
Abstract:
Dyslipidemia is known as a strong risk factor for premature atherosclerotic cardiovascular disease and increased morbidity and mortality and can have an adverse effect on left ventricular function due to direct or indirect macrovascular and/or microvascular damage. Speckle-tracking echocardiography allows the assessment of subclinical cardiac dysfunction in different diseases on the basis of myocardial deformation indices, and decrease in longitudinal and circumferential strain was shown in patients with heterozygous familial hypercholesterolemia (heFH) without comorbidities. In this issue of the journal a new study presents the results in a well-defined population which included asymptomatic treatment-naive heFH individuals without known coronary/peripheral arterial disease, with normal left ventricular ejection fraction and no other risk factors as formal arterial hypertension or diabetes mellitus. A slight impairment of global longitudinal strain was present, despite normal standard echocardiographic parameters. Also, the higher rise in systolic and diastolic blood pressure of heHF patients during exercise treadmill test might reflect early preclinical hypertension. High cholesterol level may have produced endothelial dysfunction, which has been shown to be related to the extent of atherosclerotic process and cardiovascular damage. Relevant findings are reported on left ventricular strain reduction and increase in systolic/diastolic blood pressure in asymptomatic heFH males. The relationship between myocardial strain impairment and developing systemic arterial hypertension in hypercholesterolemic patients could be the subject of further subsequent investigation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease II: Pathophysiology
Hypertension II: Pathophysiology
Atherosclerosis I: Introduction
Coronary Artery Disease I: Introduction
Atherosclerosis III: Management

